Shares of AstraZeneca fell sharply following reports that the British pharmaceutical company has been engaged in discussions with its U.S. counterpart, Bristol Myers Squibb (BMS), about a potential merger that could create a nearly $400 billion pharmaceutical group. The talks, reported in early August 2026, come after several months of preliminary discussions and would result in the fourth-largest drugmaker globally by market value.

Prior to the news, AstraZeneca’s market capitalization stood at about £196 billion, but its shares dropped by around 8.9% to close near £115, wiping approximately £18 billion off its value and causing it to lose its position as the UK’s second-largest listed company to Shell. In contrast, Bristol Myers Squibb, headquartered in Princeton, New Jersey, saw its share price initially rise by 1.7% to 3%, before regaining losses mid-day in New York trading. BMS’s market value is estimated at around $133 billion.

The proposed merger would expand AstraZeneca’s footprint in the United States, a key market where it plans to invest $50 billion in research and manufacturing by 2030. AstraZeneca completed a direct listing on the New York Stock Exchange in June, a move seen as bolstering its presence in the U.S. market. BMS maintains a significant UK presence, with a British research team near Liverpool and regional commercial offices in west London.

Industry analysts are divided on the merits of the potential tie-up. Some see strategic benefits in combining two leading oncology portfolios, as both companies generate substantial revenues from cancer treatments—accounting for nearly half of AstraZeneca’s 2025 sales and over 40% of Bristol Myers’ first-half revenues in 2026. The merger could create a broader and potentially more competitive cancer drug portfolio and provide improved access to neuroscience and cell therapy markets.

However, concerns have been raised regarding regulatory challenges posed by the significant overlap in the two companies’ oncology pipelines. Antitrust experts suggest U.S. authorities, particularly under the Trump administration’s emphasis on domestic investment and manufacturing, may subject the merger to intense scrutiny. Past large deals, such as BMS’s $80 billion acquisition of Celgene in 2019, required substantial divestitures to meet regulatory conditions. The firms might face similar demands, especially considering competition in immunotherapies and other overlapping pharmaceutical areas.

Moreover, some investors and commentators question the strategic rationale behind a mega-merger of this scale. AstraZeneca has posted strong growth under CEO Pascal Soriot, with its share price more than quadrupling since he took charge in 2012 and the company confident in hitting its target of $80 billion in annual sales by 2030. Critics argue that AstraZeneca’s recent success is driven by its own drug development, smart licensing deals, and investments in the U.S. market, making a large acquisition of a major U.S. rival potentially unnecessary and risky.

Shareholders have expressed skepticism, noting that the primary beneficiary could be Bristol Myers Squibb due to its patent cliff challenges, particularly with the imminent loss of exclusivity for its major cancer drug Opdivo by 2030. Concerns also focus on whether the combined company could successfully integrate overlapping products without stifling innovation.

AstraZeneca and Bristol Myers Squibb have not publicly confirmed the status of the talks, and both companies declined to comment when approached. Industry observers note that while a deal could emerge in the near term, it may also face delays or ultimately not proceed due to financial, operational, or regulatory obstacles.